Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 2.90M
Average 7.64M
Returns on capital
Compass Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.8%
avg -22.7%
ROIC
-35.3%
avg -55.2%
ROA
-30.3%
avg -49.5%
Analysis
ROA is currently the strongest return metric at -30.3% versus its period average of -49.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Thomas J. Schuetz | Chief Executive Officer & Vice Chairman | USD 1.03M | 65 | 6.60M | 4.78% |
Barry Shin | Chief Financial Officer | USD 717K | 54 | 525.00K | 0.38% |
Jonathan Anderman | Senior Vice President, General Counsel & Corporate Secretary | USD 648K | 43 | 196.00K | 0.14% |
Bing Gong | Chief Scientific Officer | USD 445.5K | 50 | — | — |
Anna Gifford | Senior Manager of Communications & Chief of Staff | — | — | — | — |
Cynthia A. Sirard | Chief Medical Officer | — | 56 | — | — |
James Kranz | Vice President and Head of Chemistry Manufacturing & Controls | — | — | — | — |
Arjun Prasad | Chief Commercial Officer | — | 48 | 0 | <0.01% |
Neil L. Lerner | Senior Vice President & Chief Accounting Officer | — | 59 | — | — |
Karin Herrera | Senior Vice President & Head of Clinical Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 29, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$96,850.00
Sells
0
$0.00
Net Transaction Value
+$96,850.00
Net buying
Most Active
Lerner Neil
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 1, 26Oct 1, 2026 | Lerner Neil Direct | Buy | $18.4K$18,400.00 |
| Sep 24, 26Sep 24, 2026 | Lerner Neil Direct | Buy | $2.8K$2,850.00 |
| Apr 29, 26Apr 29, 2026 | Lerner Neil Direct | Buy | $28.4K$28,350.00 |
| Apr 29, 26Apr 29, 2026 | Anderman Jonathan Direct | Buy | $47.3K$47,250.00 |
Summary
Insiders reported 4 buys worth $96,850.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $96,850.00. Lerner Neil was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A11 analysts |
| Revenue | N/A | N/A | N/A | N/A12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Compass Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about CMPX's management, answered from reported figures.
Who manages CMPX?
Compass Therapeutics, Inc. (CMPX) lists 10 active executives. The top listed executive is Anna Gifford, Senior Manager of Communications & Chief of Staff.
Are CMPX insiders buying or selling?
Recent insider activity shows net buying of $140.61M.
Continue the stock analysis
Jump to another research area for this company.